Status:
COMPLETED
Immunological Consequences of Obstructive Sleep Apnea
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Obstructive Sleep Apnea
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Obstructive sleep apnea (OSA) is a medical problem whose importance is increasing in recognition and awareness. OSA is associated with the development of hypertension and other cardiovascular diseases...
Eligibility Criteria
Inclusion
- Absence of any immunocompromising diseases or medical conditions
- Not taking any immune modifying medications or supplements
- Significant obstructive sleep apnea as verified by complete overnight polysomnography with apnea-hypopnea index (AHI) \> 15 events per hour (sleep apnea subjects)
- Free of sleep disordered breathing verified by complete overnight polysomnography (AHI \< 5 events per hour) or oximetry (\< 5 desaturations per hour) (control subjects)
Exclusion
- Documented history of allergy to influenza vaccine or any of its components
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00214071
Start Date
October 1 2004
End Date
June 1 2006
Last Update
October 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53719